Biechele Royce Advisors’s Merck MRK Stock Holding History

Biechele Royce Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,023	Closed	-$220K	–	50
2018 Q4	$220K	Sell	3,023 -247	-8%	-$17.4K	0.16%	45
2018 Q3	$221K	Buy	+3,270	New	+$208K	0.14%	46
2018 Q1	–	Sell	-8,470	Closed	-$454K	–	49
2017 Q4	$454K	Buy	+8,470	New	+$470K	0.31%	42

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Biechele Royce Advisors's MRK Position: Q1 2019 in Review

Biechele Royce Advisors sold out of Merck (MRK) in Q1 2019, closing a stake of 3,023 shares — an estimated $220K sold.

Biechele Royce Advisors first reported a position in MRK in Q4 2017 and held it in 3 quarters. The position peaked at $454K in Q4 2017. 2,293 funds tracked by Wall St. Rank hold MRK as of Q1 2019.

Biechele Royce Advisors reported no remaining Merck position as of Q1 2019 after selling out during the quarter.
Biechele Royce Advisors sold 3,023 Merck shares in Q1 2019, an estimated $220K.
Biechele Royce Advisors first reported a position in Merck in Q4 2017 and held it in 3 quarters.
Biechele Royce Advisors's Merck position peaked at $454K in Q4 2017.
2,293 funds tracked by Wall St. Rank held Merck as of Q1 2019.

Based on Biechele Royce Advisors's 13F filing for Q1 2019, filed 17 Apr 2019.